Drug
Dasiglucagon
Dasiglucagon: highest development phase Phase 3, developed by Zealand Pharma. 11 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Zealand Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dasiglucagon NCT03688711 | Phase 3 | Hypoglycemia |
| dasiglucagon NCT03941236 | Phase 3 | Congenital Hyperinsulinism |
| Dasiglucagon NCT03378635 | Phase 3 | Hypoglycemia |
| Dasiglucagon NCT03777176 | Phase 3 | Congenital Hyperinsulinism |
| Dasiglucagon NCT05378672 | Phase 3 | Hypoglycemia |
| dasiglucagon NCT03216226 | Phase 3 | Hypoglycemia |
| dasiglucagon NCT03895697 | Phase 3 | Hypoglycemia |
| dasiglucagon NCT04172441 | Phase 2/3 | Congenital Hyperinsulinism |
| Dasiglucagon NCT04836273 | Phase 2 | Hyperinsulinemic Hypoglycemia |
| Dasiglucagon NCT04824872 | Phase 2 | Hypoglycemia |
| Dasiglucagon NCT03735225 | Phase 1 | Hypoglycemia |
Latest
No recent events.
Follow Dasiglucagon on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.